Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 198

1.

[Oral contraceptive pill and thrombotic risk: epidemiological studies].

Fruzzetti F, Perini D, Spirito N, Manca R.

Minerva Ginecol. 2012 Dec;64(6):539-49. Review. Italian.

PMID:
23232538
2.
3.

Estrogen and progestin components of oral contraceptives: relationship to vascular disease.

Carr BR, Ory H.

Contraception. 1997 May;55(5):267-72. Review.

PMID:
9220222
4.
5.

Oral contraceptive use and venous thromboembolism: a consideration of the impact of bias and confounding factors on epidemiological studies.

Rekers H, Norpoth T, Michaels MA.

Eur J Contracept Reprod Health Care. 1996 Mar-May;1(1):21-30. Review.

PMID:
9678134
6.

Use of oral contraceptives containing gestodene and risk of venous thromboembolism: outlook 10 years after the third-generation "pill scare".

Heinemann LA, Dinger JC, Assmann A, Minh TD.

Contraception. 2010 May;81(5):401-7. doi: 10.1016/j.contraception.2009.12.014. Epub 2010 Jan 27.

PMID:
20399946
7.

Smoking and use of oral contraceptives: impact on thrombotic diseases.

Lidegaard O.

Am J Obstet Gynecol. 1999 Jun;180(6 Pt 2):S357-63.

PMID:
10368521
8.
9.

Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives.

Raps M, Helmerhorst F, Fleischer K, Thomassen S, Rosendaal F, Rosing J, Ballieux B, VAN Vliet H.

J Thromb Haemost. 2012 Jun;10(6):992-7. doi: 10.1111/j.1538-7836.2012.04720.x.

10.

Epidemiology of hormonal contraceptives-related venous thromboembolism.

Hugon-Rodin J, Gompel A, Plu-Bureau G.

Eur J Endocrinol. 2014 Dec;171(6):R221-30. doi: 10.1530/EJE-14-0527. Epub 2014 Jul 10. Review.

11.

[Contraceptive agents and risk of thrombosis].

Maurer-Major E, Keller PJ.

Praxis (Bern 1994). 1997 Oct 1;86(40):1543-8. Review. German.

PMID:
9417570
12.

Oral contraceptives and thrombotic disease: risk of venous thromboembolism.

Helmerhorst FM, Bloemenkamp KW, Rosendaal FR, Vandenbroucke JP.

Thromb Haemost. 1997 Jul;78(1):327-33. Review.

PMID:
9198174
14.

Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9.

Lidegaard Ø, Nielsen LH, Skovlund CW, Skjeldestad FE, Løkkegaard E.

BMJ. 2011 Oct 25;343:d6423. doi: 10.1136/bmj.d6423.

15.

Venous thromboembolism and combined oral contraceptives: does the type of progestogen make a difference?

Lawrenson R, Farmer R.

Contraception. 2000 Aug;62(2 Suppl):21S-28S; discussion 37S-38S. Review.

PMID:
11102599
16.

Thyroid function, activated protein C resistance and the risk of venous thrombosis in users of hormonal contraceptives.

Raps M, Curvers J, Helmerhorst FM, Ballieux BE, Rosing J, Thomassen S, Rosendaal FR, van Vliet HA.

Thromb Res. 2014 Apr;133(4):640-4. doi: 10.1016/j.thromres.2013.12.041. Epub 2014 Jan 7.

PMID:
24438944
17.
18.

The risks of venous thromboembolic disease among German women using oral contraceptives: a database study.

Farmer RD, Todd JC, Lewis MA, MacRae KD, Williams TJ.

Contraception. 1998 Feb;57(2):67-70.

PMID:
9589831
19.

Epidemiology of the contraceptive pill and venous thromboembolism.

Hannaford PC.

Thromb Res. 2011 Feb;127 Suppl 3:S30-4. doi: 10.1016/S0049-3848(11)70009-3. Review.

PMID:
21262435
20.

Oral contraceptives and venous thromboembolism: an epidemiological review.

Lidegaard O.

Eur J Contracept Reprod Health Care. 1996 Mar-May;1(1):13-20. Review.

PMID:
9678133

Supplemental Content

Support Center